Migraine Drugs Market Research Report Information By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2030

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL MIGRAINE DRUGS MARKET, BY TYPE

6.1. Overview

6.2. Episodic Migraine

6.2.1. Market Estimates & Forecast, by Region, 2020-2027

6.2.2. Market Estimates & Forecast, by Country, 2020-2027

6.3. Chronic Migraine

6.3.1. Market Estimates & Forecast, by Region, 2020-2027

6.3.2. Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Acute

7.2.1. Market Estimates & Forecast, by Region, 2020-2027

7.2.2. Market Estimates & Forecast, by Country, 2020-2027

7.3. Preventive

7.3.1. Market Estimates & Forecast, by Region, 2020-2027

7.3.2. Market Estimates & Forecast, by Country, 2020-2027

7.4. Neuromodulation

7.4.1. Market Estimates & Forecast, by Region, 2020-2027

7.4.2. Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

8. GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS

8.1. Overview

8.2. Beta Blockers

8.2.1. Market Estimates & Forecast, by Region, 2020-2027

8.2.2. Market Estimates & Forecast, by Country, 2020-2027

8.3. Angiotensin Blockers

8.3.1. Market Estimates & Forecast, by Region, 2020-2027

8.3.2. Market Estimates & Forecast, by Country, 2020-2027

8.4. Tricyclics

8.4.1. Market Estimates & Forecast, by Region, 2020-2027

8.4.2. Market Estimates & Forecast, by Country, 2020-2027

8.5. Anticonvulsants

8.5.1. Market Estimates & Forecast, by Region, 2020-2027

8.5.2. Market Estimates & Forecast, by Country, 2020-2027

8.6. Triptans

8.6.1. Market Estimates & Forecast, by Region, 2020-2027

8.6.2. Market Estimates & Forecast, by Country, 2020-2027

8.7. Others

9. GLOBAL MIGRAINE DRUGS MARKET, BY END USER

9.1. Overview

9.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Online Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL MIGRAINE DRUGS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. UK

10.3.1.4. Italy

10.3.1.5. Spain

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPETITIVE LANDSCAPE

11.1. Introduction

11.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Allergan Plc

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Product Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Alder Biopharmaceuticals, Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Product Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Pfizer Inc

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Product Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. GlaxoSmithKline Plc

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Product Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Merck & Co., Inc.

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Product Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Teva Pharmaceutical Industries Ltd

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Product Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. AstraZeneca Plc

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Product Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Johnson & Johnson Services, Inc.

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Product Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Amgen Inc

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Product Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Eli Lilly and Company

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Product Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. eNeura Inc.

12.11.1. Company Overview

12.11.2. Financial Overview

12.11.3. Product Offered

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Others

13. APPENDIX

13.1.1. Discussion Blueprint

13.1.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

 In section 10, only the top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

 Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.

LIST OF TABLES

TABLE 1 GLOBAL MIGRAINE DRUGS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL MIGRAINE DRUGS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL MIGRAINE DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL MIGRAINE DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 12 US: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 15 CANADA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 4 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 5 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY DRUG CLASS, 2020 (%)

FIGURE 6 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: MIGRAINE DRUGS MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL MIGRAINE DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ALLERGAN PLC.: KEY FINANCIALS

FIGURE 16 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 17 ALLERGAN PLC: REGIONAL REVENUE

FIGURE 18 PFIZER INC.: KEY FINANCIALS

FIGURE 19 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 20 PFIZER INC.: REGIONAL REVENUE

FIGURE 21 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 22 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 23 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 24 MERCK & CO., INC. KEY FINANCIALS

FIGURE 25 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 26 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 27 TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY FINANCIALS

FIGURE 28 TEVA PHARMACEUTICALS INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 29 TEVA PHARMACEUTICALS INDUSTRIES LTD: REGIONAL REVENUE

FIGURE 30 ASTRAZENECA PLC: KEY FINANCIALS

FIGURE 31 ASTRAZENECA PLC: SEGMENTAL REVENUE

FIGURE 32 ASTRAZENECA PLC: REGIONAL REVENUE

FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 36 AMGEN INC: KEY FINANCIALS

FIGURE 37 AMGEN INC: SEGMENTAL REVENUE

FIGURE 38 AMGEN INC: REGIONAL REVENUE

FIGURE 39 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 40 ELI LILLY AND COMPANYSEGMENTAL REVENUE

FIGURE 41 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 42 ENERA INC: KEY FINANCIALS

FIGURE 43 ENERA INC: SEGMENTAL REVENUE

FIGURE 44 ENERA INC: REGIONAL REVENUE